--- title: "China SXT Pharmaceuticals (SXTC) news: offering" url: "https://aibio.space/companies/china-sxt-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SXTC offering news: China SXT ends purchasers' right to buy up to $12 million more shares. China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC), China." --- SXTC China SXT Pharmaceuticals, Inc. NASDAQ · China # China SXT Pharmaceuticals (SXTC) news SXTC offering news Financings · 2026-10-21 ## [China SXT ends purchasers' right to buy up to $12 million more shares](https://aibio.space/news/china-sxt-ends-purchasers-right-buy-up-12-million-more-shares/) China SXT and the purchasers in its October 8, 2026 registered direct offering agreed to cancel, in full, a right to buy up to $12 million more shares. The company says the offering's securities already issued are not affected. ## Latest China SXT Pharmaceuticals news 1. 2026-08-28 Listings [China SXT cuts pre-paid share purchase floor price back to $0.20 from $16.00](https://aibio.space/news/china-sxt-cuts-pre-paid-share-purchase-floor-price-back-0-20-16-00/) The July 3, 2026 agreement allows pre-paid purchases of up to $31,500,000 before an original issue discount. The August 27 amendment restores the $0.20 floor after a 1-for-80 share consolidation had raised it to $16.00. 2. 2025-05-19 Financings [China SXT sells 10,000,000 shares with warrants for $5,100,000 gross](https://aibio.space/news/china-sxt-sells-10-000-000-shares-warrants-5-100-000-gross/) China SXT sold 10,000,000 shares with two warrants each for a combined $0.51 a share. The warrant exercise price resets to $0.24 on the seventh day, and the warrants could cover up to 100,000,000 shares. No placement agent or underwriter was used. 3. 2025-01-27 Listings [China SXT Pharmaceuticals files securities purchase agreement priced at $0.20 per share](https://aibio.space/news/china-sxt-pharmaceuticals-files-securities-purchase-agreement-priced-0/) The January 21, 2025 agreement sells up to $2,840,000 of shares at $0.20 each, with warrants for 200 percent of each buyer's shares at $1.00. It also sets a penalty of 2.0 percent of the subscription amount for public information failures. ## China SXT Pharmaceuticals at a glance - **Ticker**: SXTC - **Listing**: NASDAQ - **Country**: China - **Cash, Mar 31, 2026**: $28.2 million ### Related companies - [Cheng Du Sheng Nuo Biotec Co.](https://aibio.space/companies/cheng-du-sheng-nuo-biotec/) SSE: 688117 - [Humanwell Healthcare (Group) Co.,Ltd.](https://aibio.space/companies/humanwell-healthcare/) SSE: 600079 - [Staidson (Beijing) Biopharmaceuticals Co.](https://aibio.space/companies/staidson-beijing-biopharmaceuticals/) SZSE: 300204 - [VISEN Pharmaceuticals](https://aibio.space/companies/visen-pharmaceuticals/) HKEX: 2561 - [Zhejiang Wolwo Bio-Pharmaceutical Co.](https://aibio.space/companies/zhejiang-wolwo-bio-pharmaceutical/) SZSE: 300357 - [Wanbangde Pharmaceutical Holding Group Co.](https://aibio.space/companies/wanbangde-pharmaceutical/) SZSE: 002082 - [Jinghua Pharmaceutical Group Co.](https://aibio.space/companies/jinghua-pharmaceutical/) SZSE: 002349 - [China Pharma Holdings](https://aibio.space/companies/china-pharma/) AMEX: CPHI ### Also on NASDAQ - [Lyell Immunopharma](https://aibio.space/companies/lyell-immunopharma/) LYEL - [Novavax](https://aibio.space/companies/novavax/) NVAX - [Kardigan](https://aibio.space/companies/kardigan/) KARD - [10x Genomics](https://aibio.space/companies/10x-genomics/) TXG - [Immix Biopharma](https://aibio.space/companies/immix-biopharma/) IMMX - [DiaMedica Therapeutics](https://aibio.space/companies/diamedica-therapeutics/) DMAC ## What China SXT Pharmaceuticals does China SXT Pharmaceuticals, Inc. is an offshore holding company that conducts all of its business through its subsidiaries and a variable interest entity, Taizhou Suxuantang, in China. It describes itself as an innovative pharmaceutical company based in China that focuses on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine products, called TCMP. The company says its TCMP products are generic drugs whose origin, quality standard and dosage are documented in the China Pharmacopoeia. It sells three types: Advanced TCMP, which requires specialized equipment and more manufacturing steps; Fine TCMP, made with more refined ingredients; and Regular TCMP. The company reports that it has produced and marketed 11 Advanced TCMPs, has 5 Fine TCMPs and 200 Regular TCMPs, and has 200 raw medicinal materials. For the fiscal year ended March 31, 2026, Regular TCMP contributed 95.02% of total revenue and Advanced TCMP contributed 4.35%. | Product or program | What it is | Stage | |---|---|---| | Advanced TCMP | Traditional Chinese Medicine product requiring specialized equipment and more manufacturing steps | | | Fine TCMP | Traditional Chinese Medicine product made with more refined ingredients than Regular TCMP | | | Regular TCMP | Traditional Chinese Medicine product, the largest share of revenue | | Summarised from the company's [20-F filed Jul 1, 2026](https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/ea0295524-20f_chinasxt.htm). ## China SXT Pharmaceuticals annual financials | Line | FY ended Mar 31, 2026 | FY ended Mar 31, 2025 | |---|---|---| | Net income (loss) | [-$6.2 million](https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/) | [-$3.3 million](https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/) | | Cash from operations | [-$4.0 million](https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/) | [-$2.3 million](https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/) | | Cash and equivalents | [$28.2 million](https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/) | [$18.1 million](https://www.sec.gov/Archives/edgar/data/1723980/000121390026074310/) | Latest balance sheet, Mar 31, 2026 (20-F): cash and equivalents $28.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about China SXT Pharmaceuticals Has China SXT Pharmaceuticals raised money recently? Our latest story on this, dated Oct 21, 2026: "China SXT ends purchasers' right to buy up to $12 million more shares". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/china-sxt-ends-purchasers-right-buy-up-12-million-more-shares/). What is the ticker symbol of China SXT Pharmaceuticals? China SXT Pharmaceuticals, Inc. trades under the ticker SXTC on NASDAQ. Where is China SXT Pharmaceuticals listed? China SXT Pharmaceuticals, Inc. is listed on NASDAQ. What is the SEC CIK of China SXT Pharmaceuticals? The SEC Central Index Key (CIK) for China SXT Pharmaceuticals, Inc. is 1723980. Its filings are on SEC EDGAR. How many shares does China SXT Pharmaceuticals have outstanding? 958,077 shares as of 2026-03-31, per the cover page of its 20-F filed 2026-07-01. Which country or territory is China SXT Pharmaceuticals listed under? Our directory records China SXT Pharmaceuticals, Inc. under China. What does China SXT Pharmaceuticals do? Our directory classifies China SXT Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of China SXT Pharmaceuticals? The ISIN recorded for China SXT Pharmaceuticals, Inc. is VGG2161P1734. Does aibio.space cover China SXT Pharmaceuticals? aibio.space lists China SXT Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is China SXT Pharmaceuticals incorporated? SEC records list its state or country of incorporation as D8. What does China SXT Pharmaceuticals develop? China SXT Pharmaceuticals, Inc. is an offshore holding company that conducts all of its business through its subsidiaries and a variable interest entity, Taizhou Suxuantang, in China. It describes itself as an innovative pharmaceutical company based in China that focuses on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine products, called TCMP. What is Advanced TCMP from China SXT Pharmaceuticals? Advanced TCMP: Traditional Chinese Medicine product requiring specialized equipment and more manufacturing steps What is Fine TCMP from China SXT Pharmaceuticals? Fine TCMP: Traditional Chinese Medicine product made with more refined ingredients than Regular TCMP Is China SXT Pharmaceuticals profitable? China SXT Pharmaceuticals, Inc. reported a net loss of $6.2 million for the fiscal year ended Mar 31, 2026, and used $4.0 million of cash in operations, per its annual report to the SEC. How much cash does China SXT Pharmaceuticals have? $28.2 million in cash at Mar 31, 2026, per its 20-F. ## Investor discussion: China SXT Pharmaceuticals Members talk about China SXT Pharmaceuticals (SXTC). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at China SXT Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-10-21 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1723980/000121390026111404/ea030919801ex99-1.htm) 2. 2026-08-28 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1723980/000121390026095147/ea0303801-6k_china.htm) 3. 2026-07-24 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1723980/000121390026081135/ea0299103-424b5_chinasxt.htm) 4. 2026-07-06 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1723980/000121390026075528/ea0296876-6k_chinasxt.htm) 5. 2026-06-01 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1723980/000121390026063590/ea0292898-424b5_chinasxt.htm) 6. 2026-01-12 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1723980/000121390026003205/ea0272507-424b5_chinasxt.htm) 7. 2025-05-19 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1723980/000121390025045088/ea0242693-424b5_chinasxt.htm) 8. 2025-03-19 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1723980/000121390025024830/ea023444201ex99-1_chinasxt.htm) 9. 2025-01-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1723980/000121390025006976/ea022875701ex99-1_chinasxt.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SXTC on TradingView](https://www.tradingview.com/symbols/NASDAQ-SXTC/). ## SEC filings and registration - **SEC name**: China SXT Pharmaceuticals, Inc. - **CIK**: 1723980 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: SXTC (Nasdaq) - **State or country of incorporation**: D8 - **Fiscal year ends**: March 31 - **Filer category**: Non-accelerated filer - **Business address**: 178 TAIDONG ROAD NORTH, TAIZHOU - **Phone**: 8652386298290 - **Shares outstanding**: 958,077 as of 2026-03-31 (20-F filed 2026-07-01) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1723980/000121390026111404/ea0309198-6k_china.htm) filed 2026-10-21 - [6-K](https://www.sec.gov/Archives/edgar/data/1723980/000121390026108557/ea0308217-6k_china.htm) filed 2026-10-09 - [424B5](https://www.sec.gov/Archives/edgar/data/1723980/000121390026108254/ea0308214-424b5_china.htm) filed 2026-10-09 - [6-K](https://www.sec.gov/Archives/edgar/data/1723980/000121390026107829/ea0308094-6k_chinasxt.htm) filed 2026-10-08 - [6-K](https://www.sec.gov/Archives/edgar/data/1723980/000121390026107719/ea0307993-6k_china.htm) filed 2026-10-08 - [6-K](https://www.sec.gov/Archives/edgar/data/1723980/000121390026095147/ea0303801-6k_china.htm) filed 2026-08-28 - [6-K](https://www.sec.gov/Archives/edgar/data/1723980/000121390026081405/ea0299108-6k_chinasxt.htm) filed 2026-07-24 - [424B5](https://www.sec.gov/Archives/edgar/data/1723980/000121390026081135/ea0299103-424b5_chinasxt.htm) filed 2026-07-24 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001723980), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details China SXT Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SXTC, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: China SXT Pharmaceuticals, Inc. - **Ticker**: SXTC - **Listing**: NASDAQ - **Country or territory**: China - **Business scope**: Pharmaceuticals: Major - **ISIN**: VGG2161P1734 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SXTC/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/china-sxt-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "China SXT Pharmaceuticals (SXTC) news: offering", 2026-10-31, https://aibio.space/companies/china-sxt-pharmaceuticals/